# Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion

> **NCT02465216** · PHASE2 · COMPLETED · sponsor: **Access to Advanced Health Institute (AAHI)** · enrollment: 60 (actual)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** ID93 + GLA-SE

## Key facts

- **NCT ID:** NCT02465216
- **Lead sponsor:** Access to Advanced Health Institute (AAHI)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-03-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02465216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02465216, "Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02465216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*